SCHEMBL4865182

SCHEMBL4865182

CN(C)C(=O)/C=C/c1cc2c(c(C(=O)O)c1)OC(c1ccccc1)(c1ccccc1)O2

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IP6K1 Q92551 1/20 0.43
IP6K2 Q9UHH9 1/20 0.43
KDM4E B2RXH2 2/20 0.39
OPRM1 P35372 1/20 0.39
OPRL1 P41146 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TRPM8 Q7Z2W7 4/20 0.37
LMNA P02545 1/20 0.37
APP P05067 1/20 0.36
ALOX5 P09917 1/20 0.35
NR4A2 P43354 1/20 0.35
CNR1 P21554 1/20 0.35
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4865191 1.00 IP6K1 (0.43) IP6K1IP6K2KDM4EOPRM1OPRL1
SCHEMBL4871141 0.89 IP6K1 (0.41) IP6K1IP6K2KDM4EOPRM1OPRL1
SCHEMBL4871137 0.89 IP6K1 (0.41) IP6K1IP6K2KDM4EOPRM1OPRL1
SCHEMBL4863795 0.77 CNR1 (0.40) SMN1; SMN2CNR1HPGD
SCHEMBL8285530 0.75 CNR1 (0.44) KDM4ECNR1POLB
SCHEMBL7834819 0.73 KDM4E (0.57) KDM4ESMN1; SMN2LMNAALOX5POLB
SCHEMBL4868360 0.72 CNR1 (0.45) KDM4ESMN1; SMN2CNR1MAPTHPGD
SCHEMBL4867081 0.72 CNR1 (0.44) KDM4ECNR1
SCHEMBL4863705 0.72 CNR1 (0.39) CNR1
SCHEMBL4860753 0.70 MCL1 (0.44) KDM4ENPC1RAB9ACNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
EP-1697394-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 EP disclosed
EP-1697394-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 EP disclosed
EP-1697394-A2 COMT INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-09-06 EP disclosed
WO-2005058228-A2 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
WO-2005058228-A2 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
US-20050137162-A1 New COMT inhibitors for the treatment of depression and impaired cognition F. HOFFMANN-LA ROCHE AG (CH) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137162-A1 New COMT inhibitors for the treatment of depression and impaired cognition COMT, MAOB, TPH1 IP6K1 4234/4885IP6K2 4479/4885KDM4E 1075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.